Litcius/Paper detail

Dual anti-viral treatment for persistent COVID-19 in immunocompromised hemato-oncological patients is associated with a favorable prognosis and minor side effects

Suzy Meijer, Ora Halutz, Amos Adler, Katya Levytskyi, Luba Tau, Michal Dekel, Ronit Cohen‐Poradosu, Evgene Katchman, David Shasha, Jacob N. Ablin, Guy Choshen, Giris Jacob, Asaf Wasserman, Merav Ingbir, Yaël C. Cohen, Chava Perry, Ron Ram, Yair Herishanu, Yael Bar‐On, Elma van Thijn, Natalie Rutsinsky, Sheri Harari, Adi Stern, Ronen Ben‐Ami, Yael Paran

2023Journal of Infection and Chemotherapy15 citationsDOI

Topics & Concepts

MedicineRitonavirInternal medicineNeutropeniaCoronavirus disease 2019 (COVID-19)LymphocytopeniaLymphomaSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)GastroenterologyViral loadImmunologyToxicityVirusDiseaseAntiretroviral therapyInfectious disease (medical specialty)LymphocyteCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19
Dual anti-viral treatment for persistent COVID-19 in immunocompromised hemato-oncological patients is associated with a favorable prognosis and minor side effects | Litcius